nivolumab,ipilimumab
bms
['yervoy', 'ipilimumab', 'nivo', 'opdivo', 'nivolumab']
"major pathologic responses (mprs) were achieved in 95% of patients with mismatch repair deficient (dmmr) colon cancer after only 4 weeks of treatment with nivolumab (opdivo) plus ipilimumab (yervoy), according to data presented at the 2022 esmo congress."
Fierce patient advocate for those with #Lynchsyndrome. 
Ls #Previvor.  
Co-creator of #GenCSM. 
@Cure_magazine Contributor. 
Liberal, nemophilist, & Spartan.